Leadership

Dr. Gallen trained initially in Philosophy (University of Florida) then trained as a Medical Scientist (M.D., Ph.D., Emory), psychiatrist (Stanford) and neurologist (UCSD) then led an innovative career as an academician (The Scripps Research Institute) where his laboratory with great collaborators pioneered the use of Magnetic Source Imaging developing the first clinical indications for the technology, made important scientific discoveries (including the first demonstration of human cerebral plasticity and of the 40 Hz current in man) and acted as a scientific spokesman supporting the NADAQ IPO of BTi. Dr. Gallen then joined Quintiles, rising to Sr. Medical Director, where he drove pivotal trials of several therapeutics that became registered for CNS and other disorders.

Dr. Gallen then became President of the nascent Premier Research Worldwide (PRWW) and with great staff innovated the first use of Remote Data Capture into the Clinical Research Organization (CRO) field, (an approach now circa >95% of CRO data handling globally), introduced Computer Assisted Research and Development (CARD) into clinical research, played a key role in developing the therapeutic that became XYREMTM led PRWW to become a public company through a NASDAQ IPO then grew the company to international status. Dr. Gallen then joined Pharmacia as VP Medical Research where he led CNS development and/or registration of several therapeutics, managed clinical operations for all therapeutic areas in the Americas, played a leadership role in the successful re-engineering of Pharmacia clinical and was promoted to Site Head R&D for the Kalamazoo site.

Dr. Gallen next became VP Clinical Operations at Wyeth where, enabled by great staff and collaborators, he led a transformative reorganization that produced top tier industry performance, created the Alliance for Clinical Excellence (ACE) with Accenture (the first large scale industry movement into use of India for data management), and developed what emerged as the Functional Services Model for managing out-sourcing, now one of the main industry models globally. Dr. Gallen next became CEO of Vancouver-based Neuromed, negotiated a large collaboration with Merck, in-licensed OROS-hydromorphone from Alza, took Neuromed public becoming CEO of Combinatorx and later, as head of R&D, registered EXALGO™. Prior to joining WEX Pharmaceuticals Inc. as CEO, Dr. Gallen was CEO of SK Biopharmaceuticals, the first Western CEO of a major Korean pharmaceutical company, led its fine staff in significant advancement – moving important therapeutics into successful late stage trials and guided the successful re-focusing of its Custom Manufacturing Business.

Dr. Tőke has broad interdisciplinary experience of more than 20 years in translational research with special focus on preclinical/clinical immunotherapy development (on the field of HIV/AIDS, allergy and cancer). Previously, her research team developed Langerhans cell-targeting immunotherapies, nanomedicine delivery systems, pharmaceutically acceptable polymer syntheses (“novel excipient”) and medical device. All of these were applied in clinical drug development. Additionally, she has strong knowledge of FDA regulations, ICH guidelines GMP manufacturing and quality system establishment. Dr. Tőke is a graduate of Budapest University of Technology and Economics, Budapest, Hungary (PhD) and of Babes-Bolyai University, Faculty of Biochemical Engineering, Cluj-Napoca, Romania (MSc).

Dr. Youssoufian is a physician-scientist with more than 25 years of experience in drug development working with seed-stage ventures to multi-national biotech and pharmaceutical corporations. After a successful academic career as a clinician, teacher and NIH-funded investigator, he held increasingly senior roles in clinical and translational science at Bristol-Myers Squibb (Head of Experimental Medicine), Sanofi Aventis (Distinguished Scientist), ImClone (CMO), Ziopharm Oncology (President of R&D and CMO), Progenics (EVP of R&D), and BIND (CMO). He supported or led the development and approval of a number of medicines including Sprycel, Taxotere, Erbitux, Cyramza, Lartruvo and Copiktra. He is an elected member of the American Society for Clinical Investigation, the recipient of many national and international awards, and the author of more than 100 publications. He received a B.S. in biology from Boston College and M.Sc./M.D. from University of Massachusetts Medical School, followed by fellowships at Johns Hopkins, Harvard and MIT.

Mr. Illés was one of the first investors in Treos Bio. Having served as a non-executive director from inception, he joined Treos as Chief Financial Officer in 2018. Mr Illés has over 20 years of experience in technology investments and corporate finance. He was a founding partner of BXR Partners LLP, the in-house investment advisory arm of BXR Group, a leading international private investment group, prior to which he had a ten-year career in investment banking with Credit Suisse First Boston in London.

A British and Hungarian citizen, Mr. Illés holds a M.Sc. degree in Business Administration (First Class Hons) from Corvinus University, Budapest and a CEMS Master degree in International Management.

As an attorney and entrepreneur, Mr. Hautman has advised technology companies in the areas of general corporate, venture capital, intellectual property protection, technology commercialization and licensing for more than 35 years. Mr. Hautman was previously a senior partner and a co-leader of the worldwide Intellectual Property Practice for the international law firm Hogan & Hartson (now Hogan Lovells) and was recognized in 2003 by Virginia Business as one of the Legal Elite of Virginia lawyers. Mr. Hautman is a graduate of the University of Virginia Law School, USA (JD), Xavier University, Cincinnati, USA (AB Summa Cum Laude) and Le Sorbonne, Paris, France (DS).

Mr. Molnár is a programmer and mathematician with more than 20 years of experience in bioinformatics and data mining on large databases. His IT team at Treos has developed algorithms to transform genetic sequence information to immunological maps, for digital antigen design and for genotype based cancer specific prognostic risk calculator. Additionally, he has experience with electronic laboratory and clinical trial management systems, as well as electronic regulatory documentation systems. Mr. Molnár is a graduate of Eötvös Loránd University, Faculty of Science, Budapest, Hungary (MsC).